Rivaroxaban Data at the American Heart Association’s Scientific Sessions 2008

November 8 - 12, 2008
New Orleans, Louisiana, USA

Data from the phase II ATLAS ACS TIMI 46 study of Xarelto® (rivaroxaban) were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

Monday, November 10, 2008 at 7:00 p.m. CET (6:00 p.m. GMT):
Investor Conference Call - Review of Rivaroxaban Data


Dr. Kemal Malik, Head of Global Development Bayer Schering Pharma
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

MP3 audio recording (presentation and discussion)

Background Information
About Xarelto®Download PDF collect (465 KB)
About Xarelto® Clinical Studies
Download PDF collect (550 KB)
About the ATLAS ACS TIMI Trial Program
Download PDF collect (354 KB)
About RECORD Studies
Download PDF collect (546 KB)
Understanding Acute Coronary Syndrome
Download PDF collect (466 KB)
The History of AnticoagulantsDownload PDF collect (506 KB)
Understanding Venous Blood ClotsDownload PDF collect (349 KB)
Download PDF collect (254 KB)

Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial